Payment overview · 2025
General Payments
$192.38
10 reported records · 8 companies
Healthcare provider profile · identity verified
Rex Harris, MD
Allopathic & Osteopathic Physicians|Family Medicine · WACO, TX · NPI 1861804627
Verified facts
What the public records show
CMS Open Payments records show Rex Harris, MD received $192.38 in general payments during 2025 across 10 reported records.
Dexcom, Inc. accounted for 19.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $36.73 | 19.1% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $33.00 | 17.1% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.69 | 14.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $27.15 | 14.1% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $20.81 | 10.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.78 | 9.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.72 | 7.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.50 | 7.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $192.38 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $36.73 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $33.00 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $27.69 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $27.15 | 1 | 2025 |
Source payment records
|
|||||
| Holter Normalized: holter |
Device | Philips North America LLC | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 532 | 133 |
| Levothyroxine Sodium | Levothyroxine Sodium | 494 | 95 |
| Atorvastatin Calcium | Atorvastatin Calcium | 450 | 127 |
| Lisinopril | Lisinopril | 397 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 374 | 101 |
| Losartan Potassium | Losartan Potassium | 330 | 96 |
| Gabapentin | Gabapentin | 309 | 88 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 295 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 289 | 84 |
| Furosemide | Furosemide | 280 | 84 |
| Hydrochlorothiazide | Hydrochlorothiazide | 250 | 73 |
| Potassium Chloride | Potassium Chloride | 239 | 73 |
| Tramadol Hcl | Tramadol Hcl | 232 | 68 |
| Trazodone Hcl | Trazodone Hcl | 217 | 47 |
| Metformin Hcl | Metformin Hcl | 203 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 195 | 55 |
| Omeprazole | Omeprazole | 189 | 58 |
| Clopidogrel | Clopidogrel Bisulfate | 173 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 172 | 48 |
| Simvastatin | Simvastatin | 172 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 167 | 80 |
| Donepezil Hcl | Donepezil Hcl | 160 | 35 |
| Sucralfate | Sucralfate | 152 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 148 | 47 |
| Clonazepam | Clonazepam | 146 | 41 |
| Sertraline Hcl | Sertraline Hcl | 144 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 139 | 44 |
| Meloxicam | Meloxicam | 138 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 44 |
| Eliquis | Apixaban | 133 | 33 |
| Carvedilol | Carvedilol | 130 | 34 |
| Allopurinol | Allopurinol | 121 | 34 |
| Cephalexin | Cephalexin | 120 | 89 |
| Prednisone | Prednisone | 120 | 78 |
| Januvia | Sitagliptin Phosphate | 111 | 15 |
| Memantine Hcl | Memantine Hcl | 110 | 21 |
| Glimepiride | Glimepiride | 105 | 27 |
| Montelukast Sodium | Montelukast Sodium | 105 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 103 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 99 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 27 |
| Mirtazapine | Mirtazapine | 95 | 26 |
| Famotidine | Famotidine | 92 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 21 |
| Lorazepam | Lorazepam | 81 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 24 |
| Metformin Hcl Er | Metformin Hcl | 80 | 21 |
| Buspirone Hcl | Buspirone Hcl | 79 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 77 | 67 |
| Ozempic | Semaglutide | 75 | 15 |
| Pregabalin | Pregabalin | 75 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 22 |
| Azithromycin | Azithromycin | 72 | 59 |
| Ondansetron Hcl | Ondansetron Hcl | 71 | 35 |
| Spironolactone | Spironolactone | 71 | 19 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 69 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 69 | 32 |
| Bupropion Xl | Bupropion Hcl | 68 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 67 | 19 |
| Finasteride | Finasteride | 66 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 65 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | 16 |
| Alprazolam | Alprazolam | 56 | 18 |
| Jardiance | Empagliflozin | 56 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 56 | 16 |
| Atenolol | Atenolol | 54 | 16 |
| Gemtesa | Vibegron | 53 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 52 | 12 |
| Celecoxib | Celecoxib | 51 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 41 |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Entresto | Sacubitril/Valsartan | 49 | suppressed |
| Baclofen | Baclofen | 45 | 19 |
| Fluconazole | Fluconazole | 42 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 42 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | 18 |
| Ibuprofen | Ibuprofen | 41 | 11 |
| Lactulose | Lactulose | 41 | suppressed |
| Temazepam | Temazepam | 41 | 12 |
| Lamotrigine | Lamotrigine | 40 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 14 |
| Diltiazem Hcl | Diltiazem Hcl | 38 | suppressed |
| Glipizide | Glipizide | 37 | suppressed |
| Torsemide | Torsemide | 37 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 29 |
| Glipizide Er | Glipizide | 35 | 11 |
| Linzess | Linaclotide | 35 | suppressed |
| Mupirocin | Mupirocin | 35 | 23 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Rybelsus | Semaglutide | 35 | suppressed |
| Estradiol | Estradiol | 34 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 14 |
| Trulicity | Dulaglutide | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 27 |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | 14 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 27 | 11 |
| Nystatin | Nystatin | 27 | 11 |
| Azelastine Hcl | Azelastine Hcl | 25 | 19 |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 25 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 12 |
| Naproxen | Naproxen | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Prolia | Denosumab | 18 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Xifaxan | Rifaximin | 16 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Admelog | Insulin Lispro | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | 12 |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $192.38 · 10 records | Dexcom, Inc. | AIRSUPRA, Dexcom G6 Transmitter, FANAPT, FREESTYLE LIBRE, Holter, JARDIANCE, Ohtuvayre, QULIPTA, UBRELVY | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error